PMH4 2-YEAR OUTCOMES OF RISPERDAL CONSTATM-THE FIRST ATYPICAL LONG ACTING INJECTABLE ANTIPSYCHOTIC- RESULTS FROM THE CANADIAN NATIONAL OUTCOMES MEASUREMENT STUDY IN SCHIZOPHRENIA
Nov 1, 2003, 00:00
10.1016/S1098-3015(10)61762-7
https://www.valueinhealthjournal.com/article/S1098-3015(10)61762-7/fulltext
Title :
PMH4 2-YEAR OUTCOMES OF RISPERDAL CONSTATM-THE FIRST ATYPICAL LONG ACTING INJECTABLE ANTIPSYCHOTIC- RESULTS FROM THE CANADIAN NATIONAL OUTCOMES MEASUREMENT STUDY IN SCHIZOPHRENIA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)61762-7&doi=10.1016/S1098-3015(10)61762-7
First page :
Section Title :
Open access? :
No
Section Order :
207